Topical roflumilast – A novel molecule for immunodermatological diseases
Indian Journal of Skin Allergy · 2025
DOI: 10.25259/ijsa_10_2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Skin Allergy, 2025. Verfasst von Abhishek De und 3 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Topical roflumilast (ROF) is a recently approved phosphodiesterase 4 inhibitor for the treatment of psoriasis. It has strong anti-inflammatory effects which are quite helpful in the management of the distressing symptoms of psoriasis, as seen in several clinical trials. It also displayed a wide range of safety and, hence, can be utilized in patients without fearing the advent of any dangerous side effects. However, more clinical data are required to find out the extended properties of this molecule and future applications in other dermatological conditions. In 2011, oral ROF (Daliresp®) received Food and Drug Administration (FDA) approval for patients with severe chronic obstructive pulmonary disease and recurrent exacerbations. More recently, in 2022, topical ROF 0.3% cream (Zorvye ™ ) obtained FDA approval for the management of plaque psoriasis in patients aged 12 years and older.
Zitieren
APA
De, A., Chakraborty, D., Datta, S., & Singh, S. (2025). Topical roflumilast – A novel molecule for immunodermatological diseases. Indian Journal of Skin Allergy. https://doi.org/10.25259/ijsa_10_2023
Vancouver
De A, Chakraborty D, Datta S, Singh S. Topical roflumilast – A novel molecule for immunodermatological diseases. Indian Journal of Skin Allergy. 2025. doi:10.25259/ijsa_10_2023
BibTeX
@article{De2025,
author = {De, Abhishek and Chakraborty, Disha and Datta, Shreya and Singh, Sushil},
title = {Topical roflumilast – A novel molecule for immunodermatological diseases},
journal = {Indian Journal of Skin Allergy},
year = {2025},
doi = {10.25259/ijsa_10_2023}
}
EUVIMED